Company Overview
Snapshot
Founded in November 2013 by Eyal Sheetrit, Eximore operates with 1–10 employees. The company has successfully raised $3.6 million across two funding rounds from four investors. Eximore is currently in the clinical trial phase for its ophthalmic drug delivery products.
Business overview
Eximore specializes in the development of ophthalmic drug delivery products within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Medical Devices. The company's core technology involves noninvasive punctal plugs designed to release glaucoma drugs over extended periods, aiming to improve patient compliance by circumventing the need for daily eye drops. Eximore serves the global healthcare market, targeting providers within the healthcare industry.
Log in to access full profile ›Company Intelligence Q&A
- When was Eximore founded?
- Eximore was founded in November 2013 by Eyal Sheetrit.
- What is Eximore's primary focus in drug delivery?
- Eximore is developing ophthalmic drug-delivery products, with an initial focus on a noninvasive punctal plug for controlled release of glaucoma drugs.
- What is the current product development stage for Eximore?
- Eximore's products, including EXP-LP and EXP-TC, are currently in the clinical trial stage.
- Which investors participated in Eximore's May 2018 funding round?
- Docor International Management also participated in this round.
- What was the total capital raised by Eximore?
- Eximore has raised a total of $3.6 million across two funding rounds.